Article
CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.
Journal of cardiovascular pharmacology - 1 Jul 2013
El-Halabi Mustapha M, Zgheib Nathalie, Mansour Nabil M, Malli Ahmad, Ghaith Ola A, Mahfouz Rami, Alam Samir, Sharara Ala I
Abstract excerpt
The aim of this study is to investigate the effect of CYP2C19 polymorphism and cotherapy with rabeprazole or esomeprazole on the antiplatelet effect of clopidogrel. Patients receiving clopidogrel 75 mg ± rabeprazole or esomeprazole underwent genotyping for CYP2C19*2 and CYP2C19*3, and vasodilator-stimulated phosphoprotein testing to measure platelet reactivity index (PRI). Two hundred thirty-nine consecutive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
